Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Endeavor Biomedicines, Inc.
St. Jude Children's Research Hospital
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fudan University
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fudan University
St. Jude Children's Research Hospital
Nationwide Children's Hospital
M.D. Anderson Cancer Center
Medical College of Wisconsin
Shandong Cancer Hospital and Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Children's National Research Institute
Fudan University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cardinal Health 414, LLC
University of Virginia
Memorial Sloan Kettering Cancer Center
Stanford University
Sarcoma Alliance for Research through Collaboration
Canadian Cancer Trials Group
Grupo Espanol de Investigacion en Sarcomas
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Eisai Inc.
Children's Oncology Group
Brown University
OHSU Knight Cancer Institute
Brown University
National Institutes of Health Clinical Center (CC)
Centre Oscar Lambret
Washington University School of Medicine
National Cancer Institute (NCI)
Samsung Medical Center
Children's Oncology Group
Eli Lilly and Company
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota